Compare PPG Industries, Inc. (PPG) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PPG Industries, Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? PPG Industries, Inc. trades at $107.4 (market cap $24.39B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 5.5× PPG Industries, Inc.'s market cap, and PPG Industries, Inc. pays a 2.7% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| PPG | VRTX | |
|---|---|---|
Market Cap | $24.39B | $134.06B |
Sector | Basic Materials | Health |
52-Week High | $131.56 | $557.96 |
52-Week Low | $94.34 | $376.62 |
Enterprise Value | $30.26B | $128.18B |
Dividend Yield | 2.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PPG Industries trades at $109.72, down 2.5% today, with a bearish technical signal and mixed earnings history. The stock shows solid fundamentals with a P/E of 15.74, net income margin of 9.57%, and a consensus analyst price target of $129.17. Recent news highlights product innovations like the ONE RANGE marine coatings and leadership changes aimed at growth. Cash flow improved in 2025 to $893M net, though 2026 projections show a slight decline.
The outlook is cautiously optimistic, supported by analyst buy ratings (55%) and strong profitability metrics, but risks include volatile earnings performance and economic sensitivity. Near-term resistance at $111 and support at $109 are key levels to watch amid current bearish technical trends.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PPG Industries, Inc.
PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
